

027 probably reflects the emergence of a new clone because MLVA clearly differentiates between clindamycin-susceptible and -resistant isolates.

**Denise Drudy, Bram Goorhuis,
Dennis Bakker, Lorraine Kyne,
Renate van den Berg,
Lynda Fenelon,
Seamus Fanning,
and Edward J. Kuijper**

Author affiliations: University College Dublin, Dublin, Ireland (D. Drudy, L. Kyne, L. Fenelon, S. Fanning); Leiden University Medical Center, Leiden, the Netherlands (B. Goorhuis, D. Bakker, R. van den Berg, E.J. Kuijper); and European Centre for Disease Prevention and Control, Stockholm, Sweden (E.J. Kuijper)

DOI: 10.3201/eid1409.071346

References

- Kuijper EJ, Coignard B, Tull P. the ESCMID Study Group for *Clostridium difficile* (ESGCD)*; EU Member States and the European Centre for Disease Prevention and Control (ECDC). Emergence of *Clostridium difficile*-associated disease in North America and Europe. *Clin Microbiol Infect*. 2006;12:2–18. DOI: 10.1111/j.1469-0691.2006.01580.x
- McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med*. 2005;353:2433–41. DOI: 10.1056/NEJMoa051590
- van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ. Typing and subtyping of *Clostridium difficile* isolates by using multiple-locus variable-number tandem-repeat analysis. *J Clin Microbiol*. 2007;45:1024–8. DOI: 10.1128/JCM.02023-06
- Marsh JW, O'Leary MM, Shutt KA, Pasculle AW, Johnson S, Gerding DN, et al. Multilocus variable-number tandem-repeat analysis for investigation of *Clostridium difficile* transmission in hospitals. *J Clin Microbiol*. 2006;44:2558–66. DOI: 10.1128/JCM.02364-05
- Fawley WN, Freeman J, Smith C, Harmanus C, van den Berg RJ, Kuijper EJ, et al. Use of highly discriminatory fingerprinting to analyze clusters of *Clostridium difficile* infection cases due to epidemic ribotype 027 strains. *J Clin Microbiol*. 2008;46:954–60. DOI: 10.1128/JCM.01764-07
- Long S, Fenelon L, Fitzgerald S, Nolan N, Burns K, Hannan M, et al. First isolation and report of clusters of *Clostridium difficile* PCR 027 cases in Ireland. *Eurosurveillance* 2007;12:E070426.3.
- Drudy D, Kyne L, O'Mahony R, Fanning S. *GyrA* mutations in fluoroquinolone-resistant *Clostridium difficile* PCR-027. *Emerg Infect Dis*. 2007;13:504–5.
- Goorhuis A, Van der Kooi T, Vaessen N, Dekker FW, Van den Berg R, Harmanus C, et al. Spread and epidemiology of *Clostridium difficile* polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. *Clin Infect Dis*. 2007;45:695–703. DOI: 10.1086/520984
- Bourgault AM, Lamothe F, Loo VG, Poirier L; CDAD-CSI Study Group. In vitro susceptibility of *Clostridium difficile* clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. *Antimicrob Agents Chemother*. 2006;50:3473–5. DOI: 10.1128/AAC.00479-06
- MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, Laing F, et al. Molecular analysis of *Clostridium difficile* PCR ribotype 027 isolates from Eastern and Western Canada. *J Clin Microbiol*. 2006;44:2147–52. DOI: 10.1128/JCM.02563-05

Address for correspondence: Denise Drudy, Centre for Food Safety, Veterinary Sciences Centre, University College Dublin, Belfield, Dublin 4, Ireland; email: denise.drudy@ucd.ie

Letters

Letters commenting on recent articles as well as letters reporting cases, outbreaks, or original research are welcome. Letters commenting on articles should contain no more than 300 words and 5 references; they are more likely to be published if submitted within 4 weeks of the original article's publication. Letters reporting cases, outbreaks, or original research should contain no more than 800 words and 10 references. They may have one Figure or Table and should not be divided into sections. All letters should contain material not previously published and include a word count.

Increasing Incidence of *Clostridium difficile*-associated Disease, Singapore

To the Editor: *Clostridium difficile*-associated disease (CDAD) has increased in incidence across North America and Europe (1). Recent reports document the emergence of an epidemic strain of *C. difficile*, NAP1/BI/027, associated with increased virulence (2,3). However, less information is available regarding CDAD epidemiology in Asia. We examined the incidence of *C. difficile* among hospitalized patients in Singapore from 2001 through 2006 and conducted a case-control study to evaluate risk factors for testing positive for *C. difficile* toxin (CDT) in our population.

Tan Tock Seng Hospital (TTSH) is a 1,200-bed, acute-care general hospital in Singapore that serves an urban population of 4 million. We calculated CDAD incidence using the number of patients testing positive for CDT per 10,000 patient days from 2001 through 2006. We used this calculation because CDT testing would have been ordered for clinical indications. CDT testing was performed by using the same ELISA (Premier Toxins A&B; Meridian Bioscience, Inc., Cincinnati, OH, USA) throughout the entire period of investigation.

Case-patients and controls were selected from patients hospitalized at TTSH from January 1 through December 31, 2004. Microbiology laboratory records were used to define 3 groups. Case-patients were defined as CDT-positive inpatients (group 1). Two sets of negative controls were defined: the first (group 2) consisted of patients who tested negative for CDT. However, because false-negatives could nullify differences between groups 1 and 2, we defined a second set of negative controls (group 3) from among 18,000 inpatients not tested for CDT.

Seventy patients were selected from each group by using a random number generator program. Forty-eight, 61, and 56 records were retrieved for groups 1, 2, and 3, respectively. Standardized forms were used to extract data from hospital medical records. Demographic data and hospitalization details, including ward type (6-bed, 4-bed, or single room), were collected. We examined antimicrobial drug use within 30 days of admission and within 30 days of CDT testing. We also evaluated the use of proton pump inhibitors (PPIs) and H2 blockers because these have been reported as risk factors (1,4–6). Outcomes ascertained included the time to discharge after CDT testing, and death within 30 days after CDT testing. The study was approved by the institutional ethics review board.

Characteristics of case-patients and controls were compared by using the Wilcoxon rank sum test for continuous variables and the Fisher exact test for categorical variables. Variables significantly associated with CDT in the univariate analysis were selected for inclusion in the multivariate regression model. A 2-sided *p* value <0.05 was considered significant for all comparisons.

CDAD incidence rose sharply from 1.49 cases per 10,000 patient-days in 2001 to 6.64 cases per 10,000 patient-days in 2006 (Figure). During the same period, the percentage of CDT-positive samples increased from 7% to 11%, while the number of samples tested increased from 906 to 3,508.

Comparing group 1 (CDT positive) with group 2 (CDT negative), a CDT-positive result was more likely to occur in those with prolonged hospital admissions (≥ 14 days) than in those who had shorter hospital stays (<7 days; odds ratio [OR] 2.59, 95% confidence interval [CI] 1.01–6.63). Of the 19 CDT-positive patients on PPIs and the 34 CDT-negative patients on PPIs, the median exposures were

14 and 7 days, respectively (*p* = 0.01). In multivariate analysis, exposure to broad-spectrum antimicrobial drugs was a borderline significant risk factor (adjusted OR 2.24, 95% CI 1.00–5.02, *p* = 0.05).

When group 1 (CDT positive) was compared with group 3 (not tested for CDT), quinolones (OR 6.67, 95% CI 1.85–24.03), anti-anaerobic antimicrobial agents (OR 7.29, 95% CI 2.39–22.26), and stay in a 6-bed ward (OR 3.15, 95% CI 1.01–9.82) were significant risk factors in multivariate analysis. Case-patients were more likely than controls to have a longer hospital stay after testing positive. The median hospital stay after CDT testing was 16 days for case-patients versus 11 days for controls (*p* = 0.03).

This study documents a 4-fold rise in CDAD incidence among hospitalized patients in Singapore from 2001 through 2006. The current incidence, 6.64 per 10,000 patient-days, is comparable to that reported by large hospitals in Canada (7), which indicates that CDAD has emerged as an important nosocomial infection in Singapore. This incidence rate, based on the number of patients (rather than

the number of isolates) who had positive CDT test results, and the rise in sample positivity from 7% to 11% suggests that the higher rates are due to a true increased occurrence rather than merely more testing.

Possible factors driving the rise in CDAD include increased use of antimicrobial agents or changes in use patterns. The volume of quinolones and broad-spectrum antimicrobial drugs used at TTSH doubled between 2002 and 2005, consistent with other studies implicating quinolones as a risk factor in CDAD (4).

Rising incidence or virulence could herald the geographic spread of new *C. difficile* strains. Given the spread of NAP1/BI/027 strains in other parts of the world, this increased incidence in Singapore should heighten vigilance for the introduction of outbreak strains into Asia.

The findings from this study have implications for hospital management and infection control. Environmental contamination has been described as a mode of transmission (1). Potential crowding in 6-bed wards may increase spread of CDAD and may be particularly relevant in busy healthcare facili-




Figure. *Clostridium difficile*-associated disease incidence, Singapore, 2001–2006.

ties in Asia. CDAD is estimated to cost the healthcare system in the United States \$3.2 billion annually (8). With longer hospitalization for persons after they test positive for CDT, as seen in our study, rising CDAD rates could increase hospital occupancy and result in excess healthcare expenditures.

CDAD in Asia is an emerging challenge that needs to be recognized. Its control will ultimately depend on priority being given to epidemiologic surveillance, infection control, and stewardship of antimicrobial agents.

**Poh Lian Lim,
Timothy M.S. Barkham,
Li Min Ling,
Frederico Dimatatac,
Tamuno Alfred,
and Brenda Ang**

Author affiliations: Tan Tock Seng Hospital, Singapore (P.L. Lim, T.M.S. Barkham, L.M. Ling, F. Dimatatac, B. Ang); and Clinical Trials & Epidemiology Research Unit, Singapore (T. Alfred)

DOI: 10.3201/eid1409.070043

References

- Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. *N Engl J Med*. 2002;346:334–9. DOI: 10.1056/NEJMc0111603
- McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med*. 2005;353:2433–41. DOI: 10.1056/NEJMoa051590
- Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med*. 2005;353:2442–9. DOI: 10.1056/NEJMoa051639
- McCusker ME, Harris AD, Perencevich E, Roghmann M-C. Fluoroquinolone use and *Clostridium difficile*-associated diarrhea. *Emerg Infect Dis*. 2003;9:730–3.
- Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ*. 2004;171:33–8. DOI: 10.1503/cmaj.1040876
- Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for *Clostridium difficile* diarrhea. *J Hosp Infect*. 2003;54:243–5. DOI: 10.1016/S0195-6701(03)00088-4
- Alfa MJ, Du T, Beda G. Survey of incidence of *Clostridium difficile* infection in Canadian hospitals and diagnostic approaches. *J Clin Microbiol*. 1998;36:2076–80.
- O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of *Clostridium difficile*-associated disease in Massachusetts hospitals: clinical and economic consequences. *Infect Control Hosp Epidemiol*. 2007;28:1219–27. DOI: 10.1086/522676

Address for correspondence: Poh Lian Lim, Department of Infectious Diseases, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433; email: pllim@post.harvard.edu

West Nile Virus in Golden Eagles, Spain, 2007

To the Editor: Although West Nile virus (WNV) has not been isolated in Spain, several recent studies provide evidence for its circulation in this country (1–5). We report isolation of WNV in Spain from 2 golden eagles (*Aquila chrysaetos*).

A captive-bred 2-year-old male golden eagle (GE-1) was released into the wild in central Spain. The bird's location was monitored daily by telemetry, and it remained within a radius of 100 km from its original release point. On September 15, 2007 (1 month after release), it was found moribund and was moved to a rehabilitation and captive breeding center for endangered raptors. Upon admission, the bird was in fair condition but debilitated and aggressive. It then became increasingly disorientated, showed a head tilt, and died 5 days

after admission, despite intensive supportive care and treatment for secondary infections.

Eleven days after admission of GE-1, an adult male golden eagle (GE-2) and an adult female Bonelli's eagle (*Hieraetus fasciatus* [BE-1]) living in pairs (with a golden eagle and a Bonelli's eagle, respectively) in enclosures were found disorientated, debilitated, and with impaired vision. Both birds were placed in isolation and received intensive supportive care; they slowly recovered. The respective pair of each bird (GE-3 and BE-2, respectively) remained asymptomatic. A magpie (MP-1) that had entered the golden eagle enclosure 5 days before admission of GE-1 was also placed in isolation, but remained healthy. After necropsy of GE-1, tissue samples (brain, kidney, and spleen) from this bird and oropharyngeal swabs from GE-2, BE-1, and MP-1 (obtained at day 11 after admission of GE-1) were subjected to virologic analysis.

Avian influenza and Newcastle disease were excluded by reverse transcription-PCR (RT-PCR) (6,7) of oropharyngeal and cloacal swabs from GE-1, GE-2, BE-1, and MP-1. Real-time RT-PCR specific for WNV (8) was conducted with brain, kidney, and spleen tissue homogenates from GE-1 and oropharyngeal swabs from GE-2, BE-1, and MP-1. All samples except that from MP-1 yielded specific WNV genome amplification products, which were confirmed after amplification and sequencing by using a previously described method (9).

Serum samples from clinically affected eagles (GE-1, GE-2, and BE-1), the magpie (MP-1), and the healthy Bonelli's eagle (BE-2) contained WNV-neutralizing antibodies detected by a virus neutralization test performed as described (4,5). A serum sample from GE-3 (asymptomatic) remained negative up to 74 days after admission of GE-1. Specificity of the neutralization test was assessed